Hercules, CA, United States of America

Michael J Bjorn


Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 295(Granted Patents)


Location History:

  • Hercules, CA (US) (1988 - 1990)
  • Millcreek, WA (US) (1997)

Company Filing History:


Years Active: 1988-1997

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Michael J. Bjorn: Innovator in Cancer Treatment

Introduction

Michael J. Bjorn, an accomplished inventor hailing from Hercules, California, has made significant contributions to the field of cancer treatment with a notable portfolio of four patents. His work primarily revolves around the development of monoclonal antibodies aimed at targeting and treating various forms of cancer, particularly breast and ovarian cancers.

Latest Patents

Among his latest patents, one focuses on "Monoclonal anti-human breast cancer antibodies." This innovation involves the preparation and characterization of murine monoclonal antibodies that selectively bind to high molecular weight mucins through immunoprecipitation tests, identifying them as IgGs or IgMs. Additionally, immunotoxins encompassing these monoclonal antibodies and cytotoxic moieties have been produced to enhance therapeutic efficacy.

Another patent that showcases his ingenuity is titled "Anti-human ovarian cancer immunotoxins and methods of use thereof." This technology involves immunotoxins that combine cytotoxic moieties with monoclonal antibodies which specifically target human ovarian cancer tissue. The claimed capabilities include achieving a cytotoxic ID50 of 10 nM or less against human ovarian cancer cells, retarding tumor growth in mammals, and extending the survival of mammals diagnosed with human ovarian cancer tumors. This patent emphasizes the identification and characterization of antigens that these monoclonal antibodies bind to, further detailing methods for killing human ovarian cancer cells.

Career Highlights

Throughout his career, Michael Bjorn has been associated with notable organizations such as Cetus Corporation and Cetus Oncology Corporation. These companies provided a platform for his innovative research and development, laying the groundwork for his impactful contributions to cancer therapies.

Collaborations

Michael has collaborated with esteemed colleagues, including Arthur E. Frankel and David B. Ring, whose combined efforts have enriched the research environment and advanced their common goals in the field of oncology.

Conclusion

Michael J. Bjorn stands as a pivotal figure in the development of targeted cancer treatments. His patents, particularly those related to monoclonal antibodies and immunotoxins, reflect a deep commitment to harnessing scientific innovation for medical advancement. Through his work, Michael continues to inspire future generations of inventors and researchers in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…